Analyst Ratings for [MNKD] MannKind Corporation

7/16/25	Resumed	Buy	X
MNKD Mannkind H.C. Wainwright
$9
4/10/25	Initiated	Outperform	X
MNKD Mannkind Mizuho
$12
2/10/25	Initiated	Outperform	X
MNKD Mannkind Wedbush
$11
12/20/24	Initiated	Overweight	X
MNKD Mannkind Wells Fargo
$9
12/19/24	Upgrades	Sec Perform Outperform	X
MNKD Mannkind RBC Capital Mkts
$7 $10
9/9/24	Resumed	Outperform	X
MNKD Mannkind Leerink Partners
$7 $8
6/13/24	Initiated	Buy	X
MNKD Mannkind Rodman & Renshaw
$8
5/14/21	Initiated	Sector Perform	X
MNKD Mannkind RBC Capital Mkts
$5
5/14/19	Initiated	Buy	X
MNKD Mannkind BTIG Research
$3
3/4/19	Initiated	Outperform	X
MNKD Mannkind SVB Leerink
$3
2/22/19	Initiated	Outperform	X
MNKD Mannkind SVB Leerink
$3
2/28/18	Downgrades	Hold Sell	X
MNKD Mannkind Maxim Group
$1

MNKD MannKind Corporation

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.